While both approaches aim to modulate TSLP-mediated pathways, the direct targeting of TSLP by antibodies like HZ-1127 could offer broader therapeutic potential in diseases where TSLP plays a pivotal role, such as asthma, allergic rhinitis, and atopic dermatitis (Fig. 3). This evidence concerns the gene TSLP and allergic rhinitis.